Austar Lifesciences Limited board of directors announced that the group is expected to record a substantial reduction of not less than 60% in consolidated profits attributable to the shareholders of the company for the six months ending June 30, 2015, as compared with the corresponding period in 2014, mainly attributable to: delay in recognition of revenue due to subsequent modification of users requirements for projects undertaken by the Group during the past few months; and decrease in gross profit margin for certain projects undertaken by the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 HKD | 0.00% |
|
+26.98% | -48.72% |
Mar. 26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-48.72% | 52.52M | |
-4.47% | 179B | |
-1.54% | 100B | |
-6.99% | 46.16B | |
+18.16% | 44.81B | |
+9.62% | 44.38B | |
+14.04% | 29.53B | |
+22.31% | 25.83B | |
-7.17% | 23.97B | |
+3.93% | 22.5B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ending June 30, 2015